CNS Drugs

, Volume 18, Issue 9, pp 597–616

Dose Response and Atypical Antipsychotics in Schizophrenia

  • Bruce J. Kinon
  • Jonna Ahl
  • Virginia L. Stauffer
  • Angela L. Hill
  • Peter F. Buckley
Review Article

DOI: 10.2165/00023210-200418090-00005

Cite this article as:
Kinon, B.J., Ahl, J., Stauffer, V.L. et al. CNS Drugs (2004) 18: 597. doi:10.2165/00023210-200418090-00005

Abstract

Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise).

Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/ day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10–20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events.

Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics.

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Bruce J. Kinon
    • 1
  • Jonna Ahl
    • 1
  • Virginia L. Stauffer
    • 1
  • Angela L. Hill
    • 1
  • Peter F. Buckley
    • 2
  1. 1.Lilly Research Laboratories, Eli Lilly and CompanyLilly Corporate CenterIndianapolisUSA
  2. 2.Department of PsychiatryMedical College of GeorgiaAugustaUSA